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INTRODUCTION
Methylphenidate (MPD) is a commonly prescribed psychostimulant used to treat attention-deficit hyperactivity disorder. It is well established that MPD binds with high affinity to the neuronal dopamine transporter (DAT) where it blocks the inward transport of dopamine (DA) (Wayment et al., 1999; Volz et al., 2005; Volz and Schenk, 2005) . In addition, MPD indirectly affects DA transport by the vesicular monoamine transporter-2 (VMAT-2), a transporter protein that is responsible for the sequestration of cytoplasmic DA. Specifically, MPD administration increases [
3 H]DA transport into non-membraneassociated (referred to herein as cytoplasmic) vesicles purified from lysates of striatal synaptosomes prepared from treated rats (Sandoval et al., 2002; Sandoval et al., 2003) .
MPD also increases DA content in the cytoplasmic vesicle subcellular fraction (Sandoval et al., 2002) . These phenomena likely result from a redistribution of VMAT-2-containing vesicles within nerve terminals away from membranes and into the cytoplasm (Sandoval et al., 2002) .
Recent attention has focused on the regulation of cytoplasmic VMAT-2-containing vesicles after in vivo pharmacological manipulation. In contrast, the present study elucidated the nature of, and the impact of MPD on, VMAT-2-associated vesicles that co-fractionate with synaptosomal membranes after osmotic lysis (referred to herein as membrane-associated vesicles). Results revealed that in striking contrast to cytoplasmic vesicular DA transport, which is characterized by Michaelis-Menten kinetics, DA transport velocity vs. substrate concentration curves in membrane-associated vesicles were of an unexpected sigmoidal shape suggesting positive cooperativity with respect to DA transport (something uncommon in membrane transport proteins and not seen in any This article has not been copyedited and formatted. The final version may differ from this version.
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Downloaded from JPET #126888 6 other vesicular neurotransmitter transporter). In addition, transport into membraneassociated vesicles was greater in total capacity in the presence of high DA concentrations than transport into cytoplasmic vesicles. Of potential therapeutic significance, MPD increased DA transport into the membrane-associated vesicles despite rapidly decreasing VMAT-2 immunoreactivity (presumably by redistributing VMAT-2-associated vesicles into the cytoplasm) and thus kinetically upregulated the membraneassociated vesicles. MPD treatment also increased both the DA content of the membrane-associated vesicle fraction and K + -stimulated DA release from striatal suspensions. Taken together, these data suggest the existence of a previously uncharacterized pool of membrane-associated VMAT-2-containing vesicles that display heretofore unreported DA transport kinetics. Of functional relevance, DA transport in this pool, and thus its capacity to affect synaptic transmission, responds to in vivo pharmacological manipulation. These findings provide not only novel insights into the physiological regulation of vesicular DA sequestration and synaptic transmission, but also into the mechanism of action of MPD. Accordingly, these data may advance the treatment of disorders involving abnormal DA disposition including substance abuse and
Parkinson's disease.
This article has not been copyedited and formatted. The final version may differ from this version. Volz et al., 2006b; Volz et al., 2006a ) was used to measure the initial velocities of inwardly directed vesicular DA transport in vesicles purified (Erickson et al., 1990; Teng et al., 1997 ) from rat striata. Using this technique, DA transport in the clearance profiles is indicated by a downward sloping line as DA is transported into synaptosomes or vesicles where the RDE can not detect it.
Each sample consisted of both striata (~60 -70 mg total wet weight) from a rat that were homogenized in ice-cold sucrose buffer and then centrifuged (800 x g for 12 min at 4 o C)
to remove nuclear debris. The resulting supernatant (S1) was centrifuged (22,000 x g for 15 min at 4 o C) to obtain the synaptosomal pellet (P2). The P2 synaptosomal pellet was then resuspended and homogenized in ice-cold water to lyse the synaptosomal membranes. Ice-cold (pH 7.5) 25 mM HEPES and 100 mM potassium tartrate were then added to the synaptosomal pellet homogenate and the resulting mixture was centrifuged (20,000 x g for 20 min at 4 o C) to form the P3 pellet, which contained the membraneThis article has not been copyedited and formatted. The final version may differ from this version. To measure vesicular DA transport, the P3 (membrane-associated vesicles) and P4
(cytoplasmic vesicles) pellets were resuspended in 300 µ l of VMAT-2 assay buffer.
Some control experiments also monitored synaptosomal (i.e. DAT-mediated) DA transport by resuspending the P2 (synaptosomal) pellet in 300 µ l of DAT assay buffer.
The resuspended pellet was placed in a cylindrical glass chamber (10 mm internal diameter with a height of 20 mm) maintained at 37 o C by a VWR International (West Chester, PA) Model 1104 Heating Recirculator and RDE voltammetry was used to measure DA transport as previously described (Volz et al., 2006b; Volz et al., 2006a (Earles et al., 1998; Volz et al., 2006b ).
This article has not been copyedited and formatted. The final version may differ from this version. The resulting vesicular DA transport velocities were fit to either the Michaelis-
or the Hill equation
with non-linear regression using GraphPad Prism V4.0 (San Diego, CA) as previously described (Segel, 1993; Motulsky and Christopoulos, 2003) . In these equations v is the transport velocity, V max is the maximal transport velocity, K m is the Michaelis-Menten constant, [DA] is the initial extravesicular concentration of exogenously added DA, K 0.5 is formally defined as the substrate concentration at half maximal transport velocity in sigmoidal response curves, and h is the Hill coefficient. The density of kinetically active VMAT-2, the catalytic rate constant, and the rate constant for DA binding to the VMAT-2 were calculated as previously described (Volz et al., 2006a) . Protein concentrations were measured using a BioRad Laboratories (Hercules, CA) Bradford protein assay.
Indicators of precision are standard errors of the mean and statistical comparisons of the results were made using a t-test.
The total amount of DA transported via the cytoplasmic and membrane-associated vesicles was determined by using RDE voltammetry to measure the amount of DA transported in the cytoplasmic and membrane-associated vesicle fractions per unit time 
Immunoreactivity
After RDE measurement of DA transport velocities, SDS-polyacrylamide gel electrophoresis and western blot analysis was performed on the synaptosome, membraneassociated vesicle, and cytoplasmic vesicle fractions as previously described Sandoval et al., 2002) . To compare DAT and VMAT-2 levels in the synaptosome, membrane-associated vesicle, and cytoplasmic vesicle fractions, the pellets were resuspended at 50 mg original striatal wet weight /ml and 80 Vesicular DA Content Vesicular DA content was measured by high performance liquid chromatography as described previously (Sandoval et al., 2003; Truong et al., 2005) . The P3 (membraneassociated vesicles) and P4 (cytoplasmic vesicles) pellets were prepared as described above and resuspended in ice-cold tissue buffer at 50 and 100 mg original striatal wet weight/ml of tissue buffer, respectively. The resuspended vesicle preparations were then sonicated for ~10 s and centrifuged ( Partisphere C18 column) that was coupled to an electrochemical detector (+ 730 mV relative to a Ag/AgCl reference electrode). The pH 2.86 mobile phase consisted of 50 mM sodium phosphate, 30 mM citric acid, 0.16 mM EDTA, 1.5 mM sodium octyl sulfate, and 10 % (v/v) methanol (Chapin et al., 1986) . Indicators of precision are standard errors of the mean and statistical comparisons of the results were made using one way ANOVA with a Tukey post test.
RDE Measurement of K + -stimulated DA Release RDE voltammetry was used to measure K + -stimulated DA release in striatal suspensions (Volz et al., 2004; Volz and Schenk, 2004) and Schenk, 1992a) . Indicators of precision are standard errors of the mean and statistical comparisons of the results were made using a t-test.
Drugs and Chemicals
Solutions were made using university-supplied deionized water that was further purified to 18 MΩ with a DIamond Water Purification System from Barnstead (Dubuque, IA). Tetrabenazine was a generous gift from Drs. Jeffrey Erickson and Helene Varoqui (Louisiana State University Health Sciences Center, New Orleans, LA) and was first dissolved in absolute ethanol before being diluted to final concentration in assay buffer as reported previously (Volz et al., 2006b Drug Abuse (Bethesda, MD). MPD doses were calculated as the free base and were dissolved in 0.9 % (w/v) saline before being administered at 1 ml/kg as indicated in the figure legends. The pH 7.4 sucrose buffer contained 320 mM sucrose, 3.8 mM NaH 2 PO 4 , and 12.7 mM Na 2 HPO 4 (Sandoval et al., 2001 ). The pH 7.5 VMAT-2 assay buffer (Erickson et al., 1990; Teng et al., 1997) consisted of 25 mM HEPES, 100 mM potassium tartrate, 0.05 mM EGTA, 0.1 mM EDTA, and 2 mM ATP-Mg +2 (with the exception of experiments designed to investigate the ATP-dependence of DA transport where the assay buffer contained no ATP-Mg +2 (Volz et al., 2006b) ). The pH 7.4 DAT assay buffer consisted of 126 mM NaCl, 4.8 mM KCl, 1.3 mM CaCl 2 , 16 mM sodium phosphate, 1.4 mM MgSO 4 , and 11 mM dextrose (Sandoval et al., 2001 ). The pH 2.5 tissue buffer consisted of 50 mM sodium phosphate, 30 mM citric acid, and 10 % (v/v) methanol (Sandoval et al., 2003; Truong et al., 2005) . VMAT-2 antibody (AB1767) was purchased from Chemicon (Temecula, CA), Na + /K + -ATPase antibody from BD Biosciences (San Jose, CA), piccolo antibody from ABCAM (Cambridge, MA), actin antibody from ICN Biotechnologies (Costa Mesa, CA), and DAT antibody was generously provided by Dr.
Roxanne Vaughan (University of North Dakota, Grand Forks, ND).
This article has not been copyedited and formatted. The final version may differ from this version. Figure 1A confirmed previous findings that a single injection of MPD (40 mg/kg, s.c.,; a dose used previously to investigate MPD-induced vesicular trafficking (Sandoval et al., 2002) ) redistributes VMAT-2 within nerve terminals, as assessed 1 h after treatment. MPD decreased VMAT-2 immunoreactivity in the membrane-associated vesicle fraction and increased VMAT-2 immunoreactivity in the cytoplasmic vesicle fraction. Actin immunoreactivity, used to demonstrate equal protein loading onto the gels, was not altered by MPD ( Figure 1B ).
RESULTS
Results presented in
Western blot analysis was conducted to estimate the relative amounts of DAT and VMAT-2 in both vesicle fractions. Virtually all of the DAT isolated from the synaptosomal fraction was present in the membrane-associated vesicle fraction ( Figure   2A ) while VMAT-2 isolated from the synaptosome was distributed between the cytoplasmic and membrane-associated vesicle fractions ( Figure 2B ) with the membraneassociated vesicle fraction containing the majority of the VMAT-2 isolated from the synaptosome. The membrane-associated vesicle fraction also contained the plasmalemmal membrane marker, Na + /K + -ATPase, and the readily releasable/active zone marker, piccolo (data not shown). Neither of these markers were detected under the assay conditions utilized (see Methods) in the cytoplasmic vesicle fraction.
Before characterizing the kinetics of DA transport in the two vesicle populations, the specificity of transport was established. This had been accomplished previously for cytoplasmic vesicles, where vesicular DA transport was demonstrated to be ATPdependent and blocked by the VMAT-2 inhibitor tetrabenazine (Volz et al., 2006b ). In the present study, 60 nM tetrabenazine, a concentration that was without effect on This article has not been copyedited and formatted. The final version may differ from this version. Figure 3A) , completely blocked DA transport in the membrane-associated vesicles ( Figure 3B ). The absence of ATP likewise inhibited DA transport in the membrane-associated vesicles ( Figure 3C ). Additionally, 100 µ M cocaine completely blocked DAT-mediated synaptosomal DA transport ( Figure   4A ) but was without effect of DA transport in the membrane associated vesicles ( Figure   4B ). These results demonstrate that membrane-associated vesicular DA transport is selectively mediated by the VMAT-2 and that the DAT does not contribute to the measured DA transport in this preparation.
Results presented in Figure 5 compare the kinetics of vesicular DA transport in the cytoplasmic and membrane-associated fractions. Figure values for the membrane-associated vesicles as assessed at 2 µ M DA (i.e., a DA concentration observed at the plateau value for cytoplasmic vesicles shown in Figure 5A but below the plateau in Figure 5B ) and at 4 µ M DA (where transport has reached a plateau value in Figure 5B ) were 47 + 4 and 81 + 11 pmol/(s x g wet weight) (N=4), respectively.
Results presented in Figure 6 demonstrate that MPD administration increased DA content, as assessed ex vivo, in both the cytoplasmic and membrane-associated vesicle concentration that was without effect on synaptosomal (i.e., DAT-mediated) DA transport ( Figure 3A ) demonstrating that the DAT in the membrane-associated vesicle fraction ( Figure 2A ) does not contribute to the observed DA transport. Further supporting this conclusion, DA transport in the membrane-associated vesicles was unaffected by cocaine at a concentration that completely blocked synaptosomal DA transport (Figure 4) . Additionally, DA transport by the DAT is Na + -and Cl --dependent (McElvain and Schenk, 1992b) and there was virtually no Na + or Cl -in the VMAT-2 assay buffer. While the possibility that there may be some small amount of DA binding to the DAT present in the membrane-associated vesicle fraction ( Figure 2A ) cannot be excluded, this negligible amount is not detectable by RDE voltammetry when VMAT-2-mediated DA transport is inhibited ( Figure 3B and C) and therefore does not influence the analysis of VMAT-2 kinetics in the membrane-associated vesicle fraction.
Further study of the membrane-associated vesicles revealed several novel findings.
First, and in striking contrast to cytoplasmic vesicular DA transport ( Figure 5A ), initial velocity vs. DA concentration curves for membrane-associated vesicles from both salineand MPD-treated animals were of an unexpected sigmoidal shape and were modeled by the Hill equation with a Hill coefficient of approximately 5 ( Figure 5B ). This is inconsistent with Michaelis-Menten kinetics (Segel, 1993; Fersht, 1998) Perlman and Sheard, 1982) . This is near the middle of the rectangular hyperbolic curve of cytoplasmic vesicles ( Figure 5A ) and in the lower portion of the sigmoidal curve of membrane-associated vesicles ( Figure 5B ). At these concentrations, total DA transport (see Materials and Methods for description of calculation) via the cytoplasmic and membrane-associated vesicles are comparable (i.e., 6 + 3 vs. 5 + 2 pmol/(s x g wet weight), respectively). If the concentration of intraneuronal DA were to rise (i.e., after drug treatment or as a consequence of a particular microenvironment), then DA transport in the cytoplasmic vesicles would be saturated while DA transport in the membrane-associated vesicles would increase dramatically.
This allows for the possibility that at least a subpopulation of the membrane-associated vesicles may function as a reserve sequestration capacity or "DA sink" to prevent cytoplasmic DA from rising to aberrant levels.
A second related novel finding of this study is that membrane-associated vesicles are capable, at high DA concentrations, of sequestering in total far more DA than the cytoplasmic vesicles. The maximal amount of DA transported in the entire cytoplasmic vesicle fraction was 9 + 2 pmol/(s x g wet weight). In contrast, DA transport values for the membrane-associated vesicles ranged from 47 + 4 (at a DA concentration observed at the plateau value for cytoplasmic vesicles) to 81 + 11 pmol/(s x g wet weight) (at a DA This article has not been copyedited and formatted. The final version may differ from this version. A third novel finding of this study is that while MPD treatment traffics VMAT-2 and associated vesicles away from membranes ( Figure 1A ), it also kinetically upregulates the decreased number of VMAT-2 remaining in the membrane-associated fraction such that a larger quantity of DA is transported ( Figure 5B ). Consistent with this finding, DA content in the membrane-associated vesicle fraction is also increased (Figure 6 ). One functional consequence of these data relates to findings that MPD post-treatment protects against the persistent dopaminergic deficits caused by treatment with the psychostimulant, methamphetamine. In particular, it has been suggested that methamphetamine promotes aberrant cytoplasmic DA accumulation and the subsequent formation of DA-associated reactive oxygen species, thus leading to long-term damage (Cubells et al., 1994; Cadet and Brannock, 1998; Fumagalli et al., 1999; Hanson et al., 2004; Volz et al., 2007a; Volz et al., 2007b) . Previous studies indicated that MPD prevented this damage by increasing DA sequestration in cytoplasmic vesicles (Sandoval et al., 2003) . The present studies expand on these findings by suggesting that the DA sequestration-promoting capacity of MPD is not limited to cytoplasmic vesicles, and that MPD-affected membrane-associated vesicles may serve as an additional, and perhaps higher capacity, "DA sink" with This article has not been copyedited and formatted. The final version may differ from this version. (Cubells et al., 1994; Jenner, 1998) , a MPD-induced kinetic upregulation of DA transport in membrane-associated vesicles may afford protection in this disease state as well.
In addition to increasing DA transport velocities and DA content in the membrane-associated vesicle fraction, MPD increased the magnitude and initial velocity of K + -stimulated DA release in striatal suspensions (Figure 7) . Because both the degree of vesicle loading and the speed of neurotransmitter release can influence receptor activation (Liu, 2003) , these findings suggest the functional consequence that in the striatum MPD treatment influences quantal synaptic transmission by increasing the rate at which DA receptors are exposed to DA, and perhaps the duration of this effect. The MPD-induced increase in DA release was not due to an inhibition of the DAT by residual MPD introduced by the original subcutaneous injection since: 1) MPD administration did not change the duration of K + -stimulated DA release (see Results); and 2) the striatal suspensions were washed six times prior to the measurement of DA release to remove any MPD that was introduced by the original subcutaneous injection. Instead, the increase was likely due to the MPD-induced kinetic upregulation of, and enhanced DA sequestration afforded by, VMAT-2.
The membrane-associated vesicles co-fractionate with synaptosomal membranes after osmotic lysis: this is supported by the observations that plasmalemmal membrane marker, Na + /K + -ATPase, the DAT, and the readily releasable/active zone marker, piccolo, are among the proteins found in this fraction. Taken together with previous findings that K + -stimulated DA release in rat striatal suspensions is both temperature-and Ca 
